Blood Pressure, Hematologic and Erythrocyte Fragility Changes in Children Suffering from Sickle Cell Anemia following Ascorbic Acid Supplementation

• Published in: Journal of tropical pediatrics (1980) 2002-12, Vol.48 (6), p.366-370
• Main Authors: Jaja, S. I., Ikotun, A. R., Gbenebitse, S., Temiye, E. O.
• Format: Article
• Language: English
• Subjects: Anemia, Sickle Cell - blood; Anemia, Sickle Cell - drug therapy; Anemia, Sickle Cell - physiopathology; Anemias. Hemoglobinopathies; Ascorbic Acid - therapeutic use; Biological and medical sciences; Blood Pressure - drug effects; Child; Child, Preschool; Data Interpretation, Statistical; Diseases of red blood cells; Erythrocytes, Abnormal - drug effects; Female; Fetal Hemoglobin - drug effects; Hematocrit; Hematologic and hematopoietic diseases; Humans; Male; Medical sciences; Nigeria; Osmotic Fragility - drug effects; Tropical medicine
• ISSN: 0142-6338; 1465-3664
• DOI: 10.1093/tropej/48.6.366

The effect of ascorbic acid supplementation (100 mg/day for 6 weeks) on blood pressure, packed cell volume, irreversibly sickled cells, per cent fetal hemoglobin, hemoglobin concentration, and erythrocyte osmotic fragility was assessed in children suffering from sickle cell anemia. Fifteen children whose ages ranged from 4 to 11 years (7.5 ± 0.75 years) were studied. Ascorbic acid supplementation reduced systolic blood pressure by 10.9 ± 3.4 mmHg (p < 0.01), diastolic blood pressure by 7.3 ± 2.0 mmHg (p < 0.01) and mean arterial pressure by 9.4 ± 2.6 mmHg (p < 0.01). It significantly increased packed cell volume (p < 0.001), hemoglobin concentration (p < 0.001) and per cent fetal hemoglobin (p < 0.001), but reduced per cent irreversibly sickled cells (p < 0.001). Ascorbic acid supplementation also abolished the long tail of the erythrocyte osmotic fragiligram and increased the resistance of the cells to lysis.